Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Raises Price Target to $110
Benzinga Newsdesk 7 months ago
NewsPrice TargetReiterationAnalyst Ratings
Piper Sandler analyst Edward Tenthoff reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and raises the price target from $105 to $110.
Piper Sandler analyst Edward Tenthoff reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and raises the price target from $105 to $110.